Cases

AMENDED MEMORANDUM OPINION BERYL A. HOWELL, District Judge. Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) has manufactured the drug quetiapine fumarate (“quetiapine”) *62 under the brand name Seroquel® (“Seroquel”) since 1997 without generic competitio

MEMORANDUM OPINION COLLEEN KOLLAR-KOTELLY, District Judge. Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) holds new drug applications for SEROQUEL® (“Seroquel”) and SEROQUEL XR® (“Seroquel XR”), antipsychotic drugs used te treat serious psychological disorders such as schizophrenia. Since AstraZeneca first obtained approval to market these drug

ORDER OF COURT The various groups of plaintiffs have collectively filed three petitions for panel rehearing and two for rehearing en banc, raising various objections to the panel opinion. This order deals primarily with the petitions for panel rehearing. None of them has merit. End-Payor Class’s Petition The End-Payor Class, seeking only panel rehearing, argues that we must remand the case with

PARKER, Justice (dissenting). I respectfully dissent from the holding of the main opinion. I do agree that the Alabama Medicaid Agency (“the AMA”) cannot claim lack of knowledge that the average wholesale price (“AWP”) was not a true average wholesale price paid, as evidenced by the fact that the AMA’s reimbursement formula for pharmacies— AWP - 10% — reduced the AWP. This formula is the product in large part of st

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 8/20/2025 6:36 PM

598 F.Supp.2d 1271 (2009) David HALLER, Plaintiff, v. ASTRAZENECA PHARMACEUTICALS LP, et al., Defendants. Case No. 6:07-cv-15733-Orl-22DAB. United States District Court, M.D. Florida, Orlando Division. February 6, 2009. *1272 F. Kenneth Bailey, Jr., Fletcher Vines Trammell, K. Camp Bailey, Michael W. Perrin, Robert W. Cowan, Bail

661 F.3d 1378 (2011) TEVA PHARMACEUTICAL INDUSTRIES LTD., Plaintiff-Appellant, v. ASTRAZENECA PHARMACEUTICALS LP and IPR Pharmaceuticals Inc., Defendants-Appellees. No. 2011-1091. United States Court of Appeals, Federal Circuit. December 1, 2011. *1379 Jeffrey D. Blake, Sutherland, Asbill & Brennan, LLP, of Atlanta, GA, argue

748 F.Supp.2d 453 (2010) TEVA PHARMACEUTICAL INDUSTRIES LTD., Plaintiff v. ASTRAZENECA PHARMACEUTICALS LP, et al., Defendants. Civil Action No. 08cv4786. United States District Court, E.D. Pennsylvania. October 20, 2010. *455 Darcy L. Jones, Jeffrey J. Toney, John L. North, Jonathan Waldrop, Kristin E. Goran, Sutherland Asbill &a;

744 F.Supp.2d 590 (2010) Jim HOOD, Attorney General of the State of Mississippi, ex rel. the State of Mississippi, Plaintiff, v. ASTRAZENECA PHARMACEUTICALS, LP, et al., Defendants. Civil Action No. 1:10CV104-8A-JAD. United States District Court, N.D. Mississippi, Eastern Division. October 7, 2010. *593 Fletcher V. Trammell, Bail

HOWARD, Circuit Judge. AstraZeneca Pharmaceuticals LP (“AstraZeneca”) appeals from the judgment of the district court, entered after a lengthy bench trial, of liability for unfair and deceptive business practices in violation of Massachusetts General Laws Chapter 93A (“Chapter 93A”). In re Pharm. Indus. Average Wholesale Price Litig., 491 F.Supp.2d 20 (D.Mass.2007). The district court found that AstraZeneca had caused

OPINION SLEET, U.S. District Judge I. INTRODUCTION AstraZeneca AB (“AstraZeneca”) filed a complaint against defendant Mylan Pharmaceuticals, Inc. (“Mylan”) on June 2, 2014, alleging patent infringement of U.S. Patent Nos. 7,951,400 (“the '400 Patent”), RE44,186 (“the Í186 Patent”), and 8,628,-799 (“the '799 Patent”). (D.I. 1.) The cause of action was triggered when Mylan fil

605 F.Supp.2d 669 (2009) Kristin BAUM, on behalf of herself and others similarly situated, Plaintiff, v. ASTRAZENECA LP, Defendants. Civil Action No. 3:2007-cv-90. United States District Court, W.D. Pennsylvania. March 31, 2009. *670 John R. Linkosky, Carnegie, PA, Joseph E. Fieschko, Jr., Fieschko & Associates, Inc., Joseph

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE JEFFERY POPE AND CYNTHIA ) POPE, ) ) Plaintiffs, ) ) C.A. No.: N20C-06-116 FAR v. ) ) ASTRAZENECA AB, ) ASTRAZENECA ) PHARMACEUTICALS LP, and

Opinion for the court filed by Circuit Judge CLEVENGER. Dissenting opinion filed by Circuit Judge PAULINE NEWMAN. CLEVENGER, Circuit Judge. Housey Pharmaceuticals, Inc. (“Hous-ey”) sued Astrazeneca UK Ltd., Astraz-eneca LP, Astrazeneca Pharmaceuticals LP, Aventis Pharmaceuticals, Inc., Bristol-Meyers Squibb Co., Merck & Co., Inc., Roche Holdings, Inc., Hoffman-La Roche Inc., Roche Laboratories, Inc

366 F.3d 1348 HOUSEY PHARMACEUTICALS, INC., Plaintiff-Appellant,v.ASTRAZENECA UK LTD., Astrazeneca LP, Astrazeneca Pharmaceuticals LP, and Aventis Pharmaceuticals, Inc., Defendants-Cross Appellants, andBristol-Myers Squibb Company, Defendant-Cross Appellant, andMerck & Co., Inc., Defendant-Cross Appellant, andRoche Holdings, Inc., Hoffmann-La Roche Inc., Roche Laboratories, Inc., and Syntex (U.S.A.) Inc., Defendants, and

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE STEPHEN M. SCIANNELLA, individually ) and on behalf of all others similarly situated, ) ) Plaintiff, ) ) v. ) C.A. No. 2023-0125-PAF ) ASTRAZENECA UK LIMITED, ) ASTRAZ

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE STEPHEN M. SCIANNELLA, individually ) and on behalf of all others similarly situated, ) ) Plaintiff, ) ) v. ) C.A. No. 2023-0125-PAF ) ASTRAZENECA UK LIMITED, ) ASTRAZ

United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued September 21, 2021 Decided January 4, 2022 No. 20-7077 JOSHUA ATCHLEY, ET AL., APPELLANTS v. ASTRAZENECA UK LIMITED, ET AL., APPELLEES Appeal from the United States District Court for the District of Columbia (No. 1:17

OPINION & ORDER DENISE COTE, District Judge: TABLE OF CONTENTS PROCEDURAL HISTORY.......................................................459 BACKGROUND................................................................461 I.Omeprazole.........................................................461 II. The First Wave Litigati

BRYSON, Circuit Judge. Apotex Corp., Apotex, Inc., and Torp-harm, Inc., (collectively, “Apotex”) and Im-pax Laboratories, Inc., appeal judgments entered against them by the United States District Court for the Southern District of New York. Apotex and Impax were defendants in a multidistrict litigation initiated by plaintiffs Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and As-trazeneca LP (collectively, “A